The Justice Department announced on May 5, 2025, that Assertio Therapeutics, Inc., formerly known as Depomed, Inc., a pharmaceutical company headquartered in Lake Forest, Illinois, has agreed to pay $3.6 million to resolve claims that Assertio violated the False Claims Act by causing the submission of false claims for the transmucosal immediate-release fentanyl drug Lazanda for individuals who did not have breakthrough cancer pain.